On December 3rd 2021, RemeGen（荣昌生物-B：09995.HK） announces that its two new biologics independently developed by the company Telitacicept (trade name: Tai’ai®) and Disitamab Vedotin (trade name: Aidexi®) have been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021), to treat systemic lupus erythematosus (SLE) and locally advanced or metastatic gastric cancer, respectively.
After Telitacicept and Disitamab Vedotin entered the National Reimbursement Drug List (NRDL), the accessibility of these drugs will be significantly improved. This means that patients could have access to the leading new drugs at a lower expense, which can reduce heavy financial burdens, and enjoy real benefits. Besides, RemeGen can also take this opportunity to increase volume of sales and gain more market shares and economic benefits.
RemeGen is an innovative biopharma company with a global vision, focusing on the discovery, development and commercialization of antibody drug conjugants (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. Now, we have more than 20 biologics candidates in development, and 7 products are in clinical trials or commercialization for more than 20 indications.
